(Q38189884)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24555907%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

review article

1 reference

title

Have we reached the limits for the treatment of diabetic nephropathy? (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24555907%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24555907%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Rayaz Malik

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24555907%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

author name string

Reza Hajhosseiny

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24555907%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Kaivan Khavandi

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24555907%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Soudeh Mashayekhi

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24555907%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

David J Goldsmith

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24555907%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

language of work or name

English

0 references

publication date

21 February 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24555907%20AND%20SRC:MED&resulttype=core&format=json

Expert Opinion on Investigational Drugs

8 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24555907%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

volume

23

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24555907%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24555907%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

page(s)

511-522

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24555907%20AND%20SRC:MED&resulttype=core&format=json

Current status and future perspectives for CKD testing

8 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.892580

Testing for chronic kidney disease: a position statement from the National Kidney Foundation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.892580

21 January 2018

Chronic kidney disease

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.892580

Histopathology of diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.892580

Renal structural changes in non-insulin-dependent diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.892580

High risks of all-cause and cardiovascular deaths in apparently healthy middle-aged people with preserved glomerular filtration rate and albuminuria: A prospective cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.892580

Chronic kidney disease: global dimension and perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.892580

The impact of CKD identification in large countries: the burden of illness

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.892580

Global estimates of the prevalence of diabetes for 2010 and 2030

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.892580

Prevalence of chronic kidney disease in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.892580

The pathogenesis of diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.892580

Advanced glycation end products, oxidative stress and diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.892580

Advanced glycation end products up-regulate gene expression found in diabetic glomerular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.892580

Advanced glycation end products induce glomerular sclerosis and albuminuria in normal rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.892580

Mechanism of perturbation of integrin-mediated cell-matrix interactions by reactive carbonyl compounds and its implication for pathogenesis of diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.892580

Advanced glycation end product (AGE) receptor 1 suppresses cell oxidant stress and activation signaling via EGF receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.892580

Advanced glycation end product-induced apoptosis and overexpression of vascular endothelial growth factor and monocyte chemoattractant protein-1 in human-cultured mesangial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.892580

Development and prevention of advanced diabetic nephropathy in RAGE-overexpressing mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.892580

RAGE drives the development of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.892580

The mechanism by which dietary AGEs are a risk to human health is via their interaction with RAGE: arguing against the motion

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.892580

Hyperglycemia-induced reactive oxygen species increase expression of the receptor for advanced glycation end products (RAGE) and RAGE ligands

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.892580

VEGF and podocytes in diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.892580

Reduction of VEGF-A and CTGF expression in diabetic nephropathy is associated with podocyte loss.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.892580

Amelioration of long-term renal changes in obese type 2 diabetic mice by a neutralizing vascular endothelial growth factor antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.892580

Transforming growth factor beta in tissue fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.892580

Elevated expression of transforming growth factor-beta and proteoglycan production in experimental glomerulonephritis. Possible role in expansion of the mesangial extracellular matrix

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.892580

Hyperglycemia and diabetic kidney disease. The case for transforming growth factor-beta as a key mediator

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.892580

Expression of transforming growth factor beta is elevated in human and experimental diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.892580

AGEs activate mesangial TGF-beta-Smad signaling via an angiotensin II type I receptor interaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.892580

A developmental nephron deficit in rats is associated with increased susceptibility to a secondary renal injury due to advanced glycation end-products.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.892580

Effect of pyridoxamine (K-163), an inhibitor of advanced glycation end products, on type 2 diabetic nephropathy in KK-A(y)/Ta mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.892580

Connective tissue growth factor is increased in plasma of type 1 diabetic patients with nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.892580

Connective tissue growth factor plays an important role in advanced glycation end product-induced tubular epithelial-to-mesenchymal transition: implications for diabetic renal disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.892580

Renal connective tissue growth factor induction in experimental diabetes is prevented by aminoguanidine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.892580

Role of reactive oxygen species in the pathogenesis of diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.892580

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.892580

The effect of ruboxistaurin on nephropathy in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.892580

Protein kinase C beta inhibitors: a new therapeutic target for diabetic nephropathy and vascular complications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.892580

Redox signaling in cardiac physiology and pathology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.892580

AMPK dysregulation promotes diabetes-related reduction of superoxide and mitochondrial function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.892580

Renoprotection and the Bardoxolone Methyl Story - Is This the Right Way Forward? A Novel View of Renoprotection in CKD Trials: A New Classification Scheme for Renoprotective Agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.892580

Combined angiotensin inhibition for the treatment of diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.892580

Candesartan reduced advanced glycation end-products accumulation and diminished nitro-oxidative stress in type 2 diabetic KK/Ta mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.892580

Reduction of the accumulation of advanced glycation end products by ACE inhibition in experimental diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.892580

Effects of ramipril in nondiabetic nephropathy: improved parameters of oxidatives stress and potential modulation of advanced glycation end products.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.892580

Effect of valsartan, an angiotensin II receptor blocker, on markers of oxidation and glycation in Japanese type 2 diabetic subjects: blood pressure-independent effect of valsartan.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.892580

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.892580

The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.892580

Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.892580

Attenuating effect of angiotensin-(1-7) on angiotensin II-mediated NAD(P)H oxidase activation in type 2 diabetic nephropathy of KK-A(y)/Ta mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.892580

Cardiorenal end points in a trial of aliskiren for type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.892580

Potential new therapeutic agents for diabetic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.892580

Amadorins: novel post-Amadori inhibitors of advanced glycation reactions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.892580

Pyridoxamine as a multifunctional pharmaceutical: targeting pathogenic glycation and oxidative damage.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.892580

A post-Amadori inhibitor pyridoxamine also inhibits chemical modification of proteins by scavenging carbonyl intermediates of carbohydrate and lipid degradation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.892580

Pyridoxamine inhibits early renal disease and dyslipidemia in the streptozotocin-diabetic rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.892580

Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.892580

Randomized trial of an inhibitor of formation of advanced glycation end products in diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.892580

Pyridorin in type 2 diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.892580

Renal pathology patterns in type II diabetes mellitus: relationship with retinopathy. The Collaborative Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.892580

Bardoxolone methyl and kidney function in CKD with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.892580

Activation of Nrf2-antioxidant signaling attenuates NFkappaB-inflammatory response and elicits apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.892580

Extremely potent triterpenoid inducers of the phase 2 response: correlations of protection against oxidant and inflammatory stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.892580

Cellular mechanisms of redox cell signalling: role of cysteine modification in controlling antioxidant defences in response to electrophilic lipid oxidation products

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.892580

Triterpenoid CDDO-Me blocks the NF-kappaB pathway by direct inhibition of IKKbeta on Cys-179.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.892580

15-deoxy-delta 12,14-prostaglandin J2 inhibits multiple steps in the NF-kappa B signaling pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.892580

Contribution of impaired Nrf2-Keap1 pathway to oxidative stress and inflammation in chronic renal failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.892580

Multiorgan autoimmune inflammation, enhanced lymphoproliferation, and impaired homeostasis of reactive oxygen species in mice lacking the antioxidant-activated transcription factor Nrf2

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.892580

A phase I first-in-human trial of bardoxolone methyl in patients with advanced solid tumors and lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.892580

The triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic-acid methyl ester has potent anti-diabetic effects in diet-induced diabetic mice and Lepr(db/db) mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.892580

Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.892580

Renoprotective role of the vitamin D receptor in diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.892580

Combination therapy with AT1 blocker and vitamin D analog markedly ameliorates diabetic nephropathy: blockade of compensatory renin increase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.892580

Combination therapy with an angiotensin-converting enzyme inhibitor and a vitamin D analog suppresses the progression of renal insufficiency in uremic rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.892580

1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.892580

1,25-dihydroxyvitamin D3 suppresses renin gene transcription by blocking the activity of the cyclic AMP response element in the renin gene promoter.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.892580

Cross talk between the renin-angiotensin-aldosterone system and vitamin D-FGF-23-klotho in chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.892580

Maxacalcitol ameliorates tubulointerstitial fibrosis in obstructed kidneys by recruiting PPM1A/VDR complex to pSmad3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.892580

Active vitamin D treatment for reduction of residual proteinuria: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.892580

A new mechanism of action of sulodexide in diabetic nephropathy: inhibits heparanase-1 and prevents FGF-2-induced renal epithelial-mesenchymal transition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.892580

Sulodexide fails to demonstrate renoprotection in overt type 2 diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.892580

Effects of endothelin receptor antagonists on the progression of diabetic nephropathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.892580

Clinical efficacy of the selective endothelin A receptor antagonist, atrasentan, in patients with diabetes and chronic kidney disease (CKD).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.892580

Avosentan for overt diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.892580

A public health perspective on CKD and obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.892580

Regular moderate exercise reduces advanced glycation and ameliorates early diabetic nephropathy in obese Zucker rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.892580

Effect of exercise on kidney function, oxidative stress, and inflammation in type 2 diabetic KK-A(y) mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.892580

Pathogenesis and novel treatment from the mouse model of type 2 diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.892580